Imperial College London
Portrait Picture

Dr. David James PINATO

Faculty of Medicine, Department of Surgery & Cancer

Clinical Reader in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2799david.pinato Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Abdelmalak:2021:10.3390/cancers13164232,
author = {Abdelmalak, R and Lythgoe, MP and Evans, J and Flynn, M and Waters, J and Webb, A and Pinato, DJ and Sharma, R},
doi = {10.3390/cancers13164232},
journal = {Cancers},
pages = {1--12},
title = {Exploration of novel prognostic markers in grade 3 neuroendocrine neoplasia},
url = {http://dx.doi.org/10.3390/cancers13164232},
volume = {13},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: High-grade neuroendocrine tumours and carcinomas (NET/NECs) behave aggressively, typically presenting at an advanced stage. Prognosis is poor, with median survival between 5 and 34 months. The mainstay of treatment is palliative systemic therapy. However, therapy carries a risk of toxicity, which can reduce quality of life. Therefore, accurate prognostic scores for risk stratification of patients with high-grade NET/NECs are needed to help guide patient management to decide whether active treatment is likely to improve overall survival (OS). We aimed to compare the prognostic ability of published prognostic scores to predict OS in a cohort of patients with high-grade NET/NECs of any primary site. Methods: Treatment, biochemical and clinicopathological data were collected retrospectively from 77 patients with high-grade NET/NECs across three hospitals between 2016 and 2020. Variables including performance status (PS), Ki-67, age at diagnosis, previous treatment and presence of liver metastases were recorded. Pre-treatment neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio, modified Glasgow prognostic score (mGPS), and gastrointestinal neuroendocrine carcinoma (GI-NEC) score were derived. Univariable and multivariable survival analyses were used to assess prognostic ability. Results: The median age of the cohort was 63 years (range: 31–85); 53% of subjects were female. Grade 3 NETs (G3-NETs) were identified in 32 patients and NECs in 45 patients. The median OS was 13.45 months (range: 0.87–65.37) with no difference observed between G3-NETs and NECs. Univariable analysis revealed that NLR (n = 72, p = 0.049), mGPS (n = 56, p = 0.003), GI-NEC score (n = 27, p = 0.0007) and Ki-67 (n = 66, p = 0.007) were significantly associated with OS. Multivariable analysis confirmed that elevated mGPS (p = 0.046), GI-NEC score (p = 0.036), and Ki-67 (p = 0.02) were independently prognostic for reduced OS across the entire cohort. mGPS was identified
AU  - Abdelmalak,R
AU  - Lythgoe,MP
AU  - Evans,J
AU  - Flynn,M
AU  - Waters,J
AU  - Webb,A
AU  - Pinato,DJ
AU  - Sharma,R
DO  - 10.3390/cancers13164232
EP  - 12
PY  - 2021///
SN  - 2072-6694
SP  - 1
TI  - Exploration of novel prognostic markers in grade 3 neuroendocrine neoplasia
T2  - Cancers
UR  - http://dx.doi.org/10.3390/cancers13164232
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000688798800001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.mdpi.com/2072-6694/13/16/4232
UR  - http://hdl.handle.net/10044/1/91823
VL  - 13
ER  -
Download